Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Farmers Insurance
Chubb
US Army
Mallinckrodt
Accenture
Teva
Covington
McKesson

Generated: February 23, 2018

DrugPatentWatch Database Preview

ELIQUIS Drug Profile

« Back to Dashboard

Which patents cover Eliquis, and what generic alternatives are available?

Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-seven patent family members in forty countries.

The generic ingredient in ELIQUIS is apixaban. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apixaban profile page.
Summary for ELIQUIS
Drug patent expirations by year for ELIQUIS
Pharmacology for ELIQUIS
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors

US Patents and Regulatory Information for ELIQUIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ELIQUIS
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 12/28/2016

Non-Orange Book US Patents for ELIQUIS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,673,810 Imidazo-heterobicycles as factor Xa inhibitors ➤ Sign Up
6,995,172 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,691,846 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,005,435 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,371,761 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,960,411 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,531,535 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,338,963 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
6,858,616 Nitrogen containing heterobicycles as factor Xa inhibitors ➤ Sign Up
8,470,854 Lactam-containing compounds and derivatives thereof as factor XA inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ELIQUIS

Supplementary Protection Certificates for ELIQUIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90029-7 Sweden ➤ Sign Up PRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518
2011 00028 Denmark ➤ Sign Up
C0042 France ➤ Sign Up PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110518
00500 Netherlands ➤ Sign Up PRODUCT NAME: APIXABAN DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518
3 Finland ➤ Sign Up
2011012,C1427415 Lithuania ➤ Sign Up PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518
C/GB11/042 United Kingdom ➤ Sign Up PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/11/691/001 20110520; UK EU/1/11/691/002 20110520; UK EU/1/11/691/003 20110520; UK EU/1/11/691/004 20110520; UK EU/1/11/691/005 20110520
888 Luxembourg ➤ Sign Up 91888, EXPIRES: 20260518
2011012 Lithuania ➤ Sign Up PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005 20110518
1427415/01 Switzerland ➤ Sign Up FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY, US
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Farmers Insurance
Baxter
US Department of Justice
Medtronic
Fuji
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot